Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 3 6Phase 1/2 2

Status

Terminated 4Unknown 1Completed 1

Sponsor Class

INDUSTRY 6OTHER 3

Study Type

Interventional 6

Sponsor

Cancer Type

Thoracic 4Gastrointestinal 2Sarcoma 1

Conditions

Non-squamous Non-small-cell Lung Cancer 1Non Squamous Non Small Cell Lung 1Gastrointestinal Stromal Tumors 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced NSCLC 1

Interventions

Carboplatin 315Paclitaxel 303Cisplatin 250Docetaxel 238pembrolizumab 230Gemcitabine 214Pemetrexed 158Capecitabine 147Rituximab 144Bevacizumab 142Dexamethasone 125Fluorouracil 121Cyclophosphamide 102Trastuzumab 100Doxorubicin 96Nivolumab 93Prednisone 92Oxaliplatin 90atezolizumab 75Leucovorin 72durvalumab 69130-nm albumin-bound paclitaxel 68Injections 66Lenalidomide 63Irinotecan 62Bortezomib 56Letrozole 54Topotecan 53Fulvestrant 53Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × famitinib × Clear all
NCT04619433 2025-09-23

A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Terminated
48 enrolled
Thoracic

Non-squamous Non-small-cell Lung Cancer

NCT04409223 2024-02-09

Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Terminated
185 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT05106335 2023-08-16

A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Terminated
1 enrolled
Thoracic

Advanced NSCLC

NCT05042375 2022-11-17

A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Unknown
450 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02390947 2020-12-22

FACT

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Completed
543 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT02766140 2019-01-18

SHR1020 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Squamous Non Small Cell Lung Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Terminated
12 enrolled
Thoracic

Non Squamous Non Small Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡